|Geron's Chief Scientific Officer To Retire|
|By Staff and Wire Reports|
|Tuesday, 08 September 2009 13:19|
News out of the Geron Corporation (Nasdaq:GERN) is that Calvin B. Harley, Ph.D., the company’s chief scientific officer (CSO) for telomerase technologies, will retire on September 15, 2009. Dr. Harley joined Geron in 1993 and served as CSO since 1996. Dr. Harley will continue a relationship with Geron in an advisory capacity.“Cal’s numerous contributions to the company and the field have enabled Geron to advance the biology of telomeres and telomerase into drug discovery and development programs and into clinical trials,” said Dr. Thomas B. Okarma, Geron’s president and chief executive officer. “It has been a privilege and a pleasure to work with Cal over the years, and I am very pleased that he will continue to contribute to Geron as a consultant.”
“I joined Geron to progress what was then the emerging field of telomere and telomerase biology towards clinical application in age-related diseases and cancer. During my 16 years at Geron, I am fortunate to have been able to do that,” said Dr. Harley. “I have decided that now is the time to retire from my full-time position, but I am delighted to continue my involvement with the company in an advisory capacity.”
Shares of the company have been steadily trading lower since July 17, 2009 when the stock price the 52 week high of $9.24.
Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., executive vice president and chief medical officer for oncology, will review Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (imetelstat - GRN163L) and its telomerase therapeutic vaccine (GRNVAC1) at the Rodman & Renshaw 11th Annual Healthcare Conference in New York, NY, at 9:35 am on Thursday, September 10, 2009.